YourChoice

YourChoice Therapeutics is developing YCT-529, the first oral, non-hormonal contraceptive for men, now in Phase 2 clinical trials. YCT-529 is a selective retinoic acid receptor-alpha (RAR-alpha) antagonist designed to block sperm production reversibly. The company was founded by Akash Bakshi (CEO) and Nadja Mannowetz (CSO), and its research has been published in Nature Communications Medicine and other peer-reviewed journals.